Login to Your Account

Clinic Roundup

Tuesday, June 7, 2011
Adolor Corp., of Exton, Pa., completed enrollment in two Phase II trials of ADL5945 in chronic, noncancer pain patients with opioid-induced constipation. More than 200 patients have enrolled in the placebo-controlled trials that are testing different doses of the µ-opioid receptor antagonist. Adolor expects to report results in the third quarter, with a pivotal trial beginning early next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription